Related Experiment Videos

Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia

Anna M Ferrara1

  • 1Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo, Padiglione Forlanini, Viale Taramelli 5, 27100 Pavia, Italy. annamaria.ferrara@unipv.it

International Journal of Antimicrobial Agents
|February 14, 2006
PubMed

Insights

Nosocomial pneumonia, a severe ICU complication, is often caused by difficult-to-treat Gram-negative bacteria. Emerging multidrug-resistant strains necessitate exploring alternative treatments like sulbactam, colistin, newer fluoroquinolones, and tetracyclines.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Nosocomial pneumonia is a severe complication in Intensive Care Unit (ICU) patients, associated with high morbidity and mortality.
  • Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia, are primary pathogens, exhibiting significant antimicrobial resistance.
  • The increasing prevalence of multidrug-resistant (MDR) strains complicates treatment strategies.

Purpose of the Study:

  • To review current antimicrobial agents effective against common Gram-negative pathogens causing nosocomial pneumonia.
  • To identify and evaluate potential alternative therapeutic options for MDR Gram-negative infections in the ICU setting.
  • To highlight the need for further clinical trials to validate novel treatment strategies.

Main Methods:

  • Literature review of antimicrobial activity against relevant Gram-negative bacteria.
  • Analysis of established and emerging treatment options for nosocomial pneumonia.
  • Assessment of resistance mechanisms and their impact on therapeutic choices.

Main Results:

  • Carbapenems, piperacillin, cefepime, ceftazidime, ciprofloxacin, and aminoglycosides show activity against P. aeruginosa.
  • Carbapenems are active against A. baumannii, and sulphamethoxazole/trimethoprim against S. maltophilia.
  • Sulbactam, colistin, newer fluoroquinolones, and tetracyclines show promise for MDR strains of A. baumannii and S. maltophilia.

Conclusions:

  • Effective management of nosocomial pneumonia requires addressing antimicrobial resistance in Gram-negative pathogens.
  • Sulbactam, colistin, newer fluoroquinolones, and tetracyclines represent promising alternatives for MDR infections.
  • Large-scale clinical trials are essential to confirm the efficacy of these alternative therapies.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...